Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Eye drop containing VEGF antagonist

An eye drop and antagonist technology, applied in the field of eye drops containing VEGF antagonist, can solve the problems of instability, limited effect, high cost and the like, and achieve the effects of saving production cost, accurate curative effect and extremely high content

Active Publication Date: 2013-07-24
CHENGDU KANGHONG BIOTECH
View PDF13 Cites 21 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the concentration of the eye drops is relatively high. Due to the instability of biological agents, many patients receiving anti-vascular therapy on the ocular surface are unwilling to be hospitalized. High concentrations of biological agents are likely to cause inconvenience in storage and use. Ocular surface administration is a special route of administration. For pH, osmotic pressure and local irritation, bacteriostats and antibacterial agents cannot be added. The above problems make the drugs used for ocular surface anti-neovascular treatment expensive and have limited effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Eye drop containing VEGF antagonist
  • Eye drop containing VEGF antagonist
  • Eye drop containing VEGF antagonist

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0053] Example 1, Conbercept Eye Drops Study on Corneal Neovascularization Induced by Alkali Burn

[0054] Drugs: Chlortetracycline Hydrochloride Eye Ointment, specification batch number: 2.0g / bottle, 411002, valid until December 2014, Chongqing Kerui Pharmaceutical Co., Ltd.; lidocaine hydrochloride injection, specification batch number: 5ml / bottle, 0.1g / bottle, Valid until April 2012, Tianjin Pharmaceutical Jiaozuo Co., Ltd.

[0055] Reagent: sodium hydroxide (NaOH), specification batch number: 500g / bottle, 20091223, Chengdu Kelong Chemical Reagent Factory.

[0056] Samples tested:

[0057] A, Conbercept eye drops (prepared according to Example 3) 10mg / ml, colorless transparent liquid, 1ml / bottle, batch number: FR1108001, stored at 2-8°C, added dropwise to the surface of the eye when used;

[0058] B, Conbercept eye drops (prepared according to Example 3) 9mg / ml, colorless transparent liquid, 1ml / bottle, batch number: FR1108002, stored at 2-8°C, added dropwise to the surfa...

Embodiment 2

[0073] Example 2 Effect of low-dose Conbercept eye drops on corneal NV growth caused by alkali burn

[0074] Drugs: Chlortetracycline Hydrochloride Eye Ointment, specification batch number: 2.0g / bottle, 411002, valid until December 2014, Chongqing Kerui Pharmaceutical Co., Ltd.; lidocaine hydrochloride injection, specification batch number: 5ml / bottle, 0.1g / bottle, Valid until April 2012, Tianjin Pharmaceutical Jiaozuo Co., Ltd.

[0075] Reagent: sodium hydroxide (NaOH), specification batch number: 500g / bottle, 20091223, Chengdu Kelong Chemical Reagent Factory.

[0076] Samples tested:

[0077] A, Conbercept Eye Drops (prepared according to Example 3) 0.5mg / ml, colorless transparent liquid, 800 μl / bottle, batch number: 20111001, stored at 2-8°C, added dropwise to the surface of the eye when used;

[0078] B, Conbercept eye drops (prepared according to Example 3) 0.1 mg / ml, colorless transparent liquid, 800 μl / bottle, batch number: 20111001, stored at 2-8°C, added dropwise to...

Embodiment 3

[0093] Embodiment 3, the preparation of Conbercept (FP3 fusion protein) eye drops

[0094] prescription:

[0095] FP3 fusion protein 10mg / ml, 9mg / ml, 5mg / ml, 1mg / ml, 0.5mg / ml, 0.1mg / ml, 0.05mg / ml or 0.01mg / ml

[0096]

[0097]

[0098] Preparation method: After thawing the concentrated FP3 fusion protein stock solution after changing the liquid, in a clean bench (sterile cabinet) of class C, add filter-sterilized solution containing 55mM citric acid, 12.5% ​​sucrose, 250mM Arginine and 0.05% Tween 20 buffer, filter, adjust FP3 fusion protein to 10mg / ml, 9mg / ml, 5mg / ml, 1mg / ml, 0.5mg / ml, 0.1mg / ml, 0.05mg / ml or 0.01mg / ml, pH 7.5-8.3, aseptically dispensed into eye drop containers and stored at 2-8°C.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an eye drop containing a VEGF antagonist. The eye drop contains the low-concentration VEGF antagonist, and especially contains the 0.05-9.0mg / ml VEGF antagonist. The eye drop can ensure the safety and the stability, and simultaneously has substantial curative effects.

Description

technical field [0001] The invention relates to the field of pharmaceutical preparations, in particular to an eye drop containing a VEGF antagonist. Background technique [0002] The incidence of ocular surface diseases such as corneal neovascularization, neovascular glaucoma, pterygium, and chronic conjunctivitis has a certain relationship with the generation of neovascularization. Overexpression of VEGF can induce ocular surface neovascularization. Corneal neovascularization is not an independent corneal disease, but a pathological change. There are many reasons for corneal neovascularization, such as immune inflammation, infection, degeneration, trauma, improper use of contact lenses, and iatrogenic diseases. If the corneal neovascularization caused by the above reasons is not treated in time, it will eventually lead to corneal blindness. Corneal neovascularization is the main cause of vision loss and blindness worldwide. About 4.14% of ophthalmic patients in the United...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K39/395A61K9/08A61K47/34A61P27/02A61P27/06
CPCA61K9/0048A61K9/08A61K39/3955A61K47/12A61K47/183A61K47/26
Inventor 柯潇郑强
Owner CHENGDU KANGHONG BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com